Separate terms with OR to return results that match either term.
 
Clear All

10,000 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
62332-0620-05 62332-0620 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0621-17 62332-0621 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
62332-0622-50 62332-0622 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Oct. 20, 2022 In Use
51662-1261-01 51662-1261 Hydrocortisone Sodium Succinate SOLU-CORTEF 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Sept. 3, 2018 In Use
51662-1261-03 51662-1261 Hydrocortisone Sodium Succinate SOLU-CORTEF 100.0 mg/2mL Hormonal Therapy Adrenal Glucocorticoid Corticosteroid Intramuscular, Intravenous Nov. 10, 2022 In Use
82009-0061-05 82009-0061 Finasteride Finasteride 5.0 mg/1 Ancillary Therapy Protective Agent 5-alpha Reductase Inhibitor Oral Nov. 21, 2022 In Use
71225-0120-01 71225-0120 BENDAMUSTINE HYDROCHLORIDE VIVIMUSTA 25.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Dec. 7, 2022 In Use
71335-2181-01 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-02 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
71335-2181-03 71335-2181 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Oct. 25, 2022 In Use
50419-0393-03 50419-0393 LAROTRECTINIB VITRAKVI 20.0 mg/mL Chemotherapy Tyrosine Kinase Inhibitor TRK OROPHARYNGEAL Dec. 6, 2022 In Use
25021-0235-50 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 29, 2014 In Use
25021-0235-51 25021-0235 Gemcitabine Hydrochloride Gemcitabine 1.0 g/25mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 15, 2022 In Use
68083-0502-01 68083-0502 MITOMYCIN MITOMYCIN 40.0 mg/80mL Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Intravenous Nov. 22, 2022 In Use
43598-0171-11 43598-0171 Thiotepa Thiotepa 100.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard /Ethylenimine Intracavitary, Intravenous, Intravesical Nov. 1, 2022 In Use
46708-0618-31 46708-0618 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
46708-0619-31 46708-0619 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
49884-0128-91 49884-0128 Everolimus Everolimus 10.0 mg/1 Chemotherapy Enzyme Inhibitor mTOR Oral Nov. 29, 2022 In Use
62332-0618-31 62332-0618 Cyclophosphamide Cyclophosphamide 25.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
62332-0619-31 62332-0619 Cyclophosphamide Cyclophosphamide 50.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Nov. 23, 2022 In Use
65219-0550-01 65219-0550 Pralatrexate Pralatrexate 20.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
65219-0552-02 65219-0552 Pralatrexate Pralatrexate 40.0 mg/2mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Nov. 15, 2022 In Use
70121-2537-06 70121-2537 Leuprolide acetate Leuprolide acetate Hormonal Therapy GnRH Agonist Subcutaneous Nov. 7, 2022 In Use
00054-0143-07 00054-0143 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Nov. 24, 2008 In Use
00054-0143-08 00054-0143 Granisetron Hydrochloride Granisetron Hydrochloride 1.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 31, 2007 In Use

Found 10,000 results in 7 millisecondsExport these results